FILE:LH/LH-8K-20100512074600.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company in connection with its Annual Meeting of Stockholders in Burlington, NC on May 12, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May 12, 2010
2010
Annual Meeting
of Stockholders
2
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  
Actual results could differ materially from those suggested by these forward-looking statements.  Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.
Forward Looking Statement
Introduction
3
Leading National Lab Provider
Fastest growing national lab
$55 Billion market
Clinical, Anatomic and Genomic Testing
Serving clients in all 50 states and Canada
Leading clinical trials testing business
2010 Priorities
4
Our Focus
  Profitable revenue growth
  IT and client connectivity
  Continue scientific
    leadership
  Maintain price
  Control costs                                    
2010 Priorities
5
Profitable Revenue Growth
  Target specialty physicians with
    breadth of menu and services
  Educate payers and physicians on
    value of LabCorp testing
  Leverage assets from Monogram
   acquisition
  Continue to improve patient experience
2010 Priorities
6
IT and Client Connectivity
  Enhance online services and
   analytic tools
  
LabCorp Inside the Box
for
   superior connectivity
  Improve Patient Experience
   through:
  Automated PSC workflow
  Patient access via PHRs,
   online appointments
  Enterprise services
   including VoIP
Continue "open platform" strategy
  to maximize options for users
Continue Scientific
Leadership
  Increase esoteric testing
  Grow and enhance offerings in
    personalized medicine:
  Expand outcome improvement
           programs
  Develop and commercialize
                  
           companion diagnostics
2010 Priorities
7
2010 Priorities
Maintain Price
  Managed care stability; offsets
   1.9% Medicare rate decrease  
  Focus on high-value tests
  Promote outcome improvement
8
Control Costs
  Continue focus on collections
    and bad debt reduction
  Optimize supply chain  
  Use efficiency gains to
    improve patient experience
2010 Priorities
9
First Quarter 2010 Results
10
2010
2009
+/(-)
Revenue
(1)
1,193.6
$
1,155.7
$     
3.3%
Adjusted Operating Income  
243.5
$   
240.5
$        
1.2%
Adjusted Operating Income Margin  
20.4%
20.8%
(40)
     
bp
Adjusted EPS
(1)
1.30
$      
1.22
$           
6.6%
Operating Cash Flow
232.0
$   
208.9
$        
11.1%
Less: Capital Expenditures
(24.5)
$     
(30.7)
$         
(20.2%)
Free Cash Flow
207.5
$   
178.2
$        
16.4%
(1) During the quarter inclement weather reduced revenue by an estimated $23 million and EPS by approximately eight cents
Three Months Ended Mar 31,
Supplemental Financial Information
11
Q1 09
Q2 09
Q3 09
Q4 09
Q1 10
Bad debt as a percentage of sales
5.30%
5.30%
5.30%
5.30%
5.05%
Days sales outstanding
52
     
50
     
48
     
44
     
46
     
A/R coverage (Allowance for Doubtful Accts. / A/R)
19.5%
20.6%
21.9%
23.2%
21.7%
Laboratory Corporation of America
Other Financial Information
FY 2009 and Q1 2010
($ in millions)
Superior Two-Year Return
LabCorp shares up 4.7%
S&P Healthcare Index down 11.3%
S&P 500 down 16.9%  
S&P Financials Index down 42.1%
Stock Performance
12
Note:  Period measured is from January 2
nd
, 2008  May 3
rd
, 2010
Source:  First Call
Key Points
  Critical position in health care delivery system
  Attractive market
  Strong competitive position - well positioned to gain share
  Leadership in personalized medicine
  Excellent cash flow
  Strong balance sheet
Conclusion
13
14
2010 LabCorp.   All rights reserved.   6967-0409


